Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- August15 2003
- Volume 10
- Issue 15
Reason for Hope
Advertisement
Although more than a few of today's doctors maybe facing serious debt burdens, they can take somecomfort in the fact that their chosen profession hasone of the best chances at success. According toBizStats (www.bizstats.com), the occupation of physicianis among the top 10 safest small businesses inthe nation—with more than 87% succeeding in 2002.
Articles in this issue
about 18 years ago
Take Steps Toward Your Second Homeabout 18 years ago
Climb over Home Improvement Obstaclesabout 18 years ago
What Companies Don't Want You to Knowabout 18 years ago
Balance Cost and Time in Your Householdabout 18 years ago
Doctors and Crime Are a Bad Combinationabout 18 years ago
What's in This Tax Relief Act for You?about 18 years ago
Confront the Perils of Retirement Todayabout 18 years ago
Know What to Do if You're Shown the Doorabout 18 years ago
Pay Attention to Retirement Allocationsabout 18 years ago
Figure Out Which Plan Will Work for YouAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5